# Emphysema Market > Emphysema Market Research Report By Type (Centrilobular, Panlobular), By Diagnosis (Imaging Test (X-Ray, Ct Scan), Lung Function Test), by Treatment (Medication (Antibiotics, Bronchodilators), Therapy, Surgery), by End-User-Global Forecast till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.83% - **2024:** $ 13.53 Billion - **2025:** $ 14.18 Billion - **2035:** $ 22.73 Billion - **Key Players:** GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Roche (CH), Pfizer(US), Teva Pharmaceutical Industries (IL), Mylan (US), Sanofi (FR) **Report ID:** MRFR/Pharma/4354-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/emphysema-market-5810 --- ## Market Summary ## **Global Emphysema Market Overview** Emphysema Market Size was valued at USD 12.23 Billion in 2023. The Global Emphysema industry is projected to grow from USD 13.53 Billion in 2024 to USD 19.83 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.64% during the forecast period (2024 - 2032). Emphysema, a lung disease is characterized by the shortness of breath, thereby, damaging the air sacs in the lungs. The disease leads to rupture and weakening of inner walls of the air sacs over the period.  The disease involves the reduction in the surface area of the lungs which in turn reduces the amount of oxygen reaching the bloodstream. Hence, during exhalation, the alveoli do not function properly leaving the air trapped in the lungs, leaving no space for oxygen-rich air to enter the lungs.  Emphysema and chronic bronchitis are together known as the Chronic Obstructive Pulmonary Disease (COPD). The patients suffering from emphysema also have chronic bronchitis. The major causes of emphysema are exposure to air pollutants, chemical fumes, and dust and smoking. The condition can be diagnosed through various tests such as imaging tests that include chest X-ray and CT scan and the lung function test. The global emphysema market is mainly driven by the high prevalence of respiratory diseases such as chronic bronchitis, emphysema, and others and a huge demand for treatment including smoking cessation drugs and [antibiotics](../../../reports/antibiotic-resistance-market-8579). Additionally, the rising availability of diagnostic services for respiratory illness also fuels the growth of the market. According to the World Health Organization, COPD affects nearly 210 million people which is attributed to the increasing population in urban areas across the globe and growing number of tobacco smokers. ## **Emphysema Market Segment Insights** The global emphysema market is segmented on the basis of type, diagnosis, treatment, and end-user. ### **Emphysema Type Insights** On the basis of type, the market is segmented into centrilobular and panlobular emphysema. ### **Emphysema Diagnosis Insights** On the basis of diagnosis, the market is segmented into imaging test, lung function test, and others. The imaging test is further segmented into chest X-ray and CT scan. ### **Emphysema Treatment Insights** On the basis of treatment, the market is segmented into medications, therapy, and surgery. Medications are further segmented into smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, and leukotriene modifiers. Therapy is further segmented into pulmonary rehabilitation, nutrition therapy, gene therapy, and supplemental oxygen. Surgery is further segmented into lung volume reduction surgery, lung transplant, and bullectomy. ### **Emphysema End-User Insights** On the basis of end-user, the market is segmented into hospitals and clinics, surgical centers, and others. ## **Regional Analysis of the Global Emphysema Market    ** The American emphysema market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of imaging test and lung function test for the diagnosis of the disease and huge population base diagnosed with COPD. Furthermore, the U.S. is the largest market in North America owing to the presence of large number of market players manufacturing medications for emphysema and increasing awareness about risk factors and cases of the disease. The American Lung Association stated that in the U.S., COPD is the fourth leading cause of deaths. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of respiratory diseases The European emphysema market exhibits a positive growth with an increasing emphasis on the diagnosis of chronic respiratory conditions such as the COPD and asthma and increasing focus on research and development activities for the treatment of respiratory diseases. Germany and the U.K. are the major contributors to the growth of the market. Additionally, increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market. Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for lung function test and other diagnostic tests and the increasing focus on early diagnosis and treatment of lung diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, rising environmental pollution and exposure to harmful chemicals also attribute to the growth of the market. The Middle Eastern and African market for emphysema exhibits a steady rise with an increase in the number of healthcare facilities providing treatment for the chronic condition and the flourishing growth of medical device sector especially the [diagnostic devices](../../../reports/diagnostic-imaging-services-market-7186) such as MRI and CT. In the African region, the awareness about COPD is increasing and is fueling the growth of the market. ## **Key Players in the Global Emphysema Market** Some of the key players in this market are **Intended Audience** ## Market Drivers ### Rising Prevalence of Emphysema The increasing prevalence of emphysema is a primary driver for The Global Emphysema Industry. According to recent data, the number of individuals diagnosed with chronic obstructive pulmonary disease (COPD), which includes emphysema, is projected to rise significantly. This trend is attributed to factors such as aging populations and lifestyle choices, including smoking and air pollution. As the global population ages, the incidence of respiratory diseases is expected to escalate, leading to a higher demand for treatment options. The World Health Organization estimates that COPD will become the third leading cause of death by 2030, underscoring the urgent need for effective management strategies within The Global Emphysema Industry. ### Growing Awareness and Education There is a notable increase in awareness and education regarding emphysema and its management, which serves as a significant driver for The Global Emphysema Industry. Public health campaigns and educational initiatives are effectively informing individuals about the risks associated with smoking and environmental factors contributing to emphysema. This heightened awareness is leading to earlier diagnosis and treatment, which is crucial for managing the disease effectively. Furthermore, healthcare professionals are increasingly emphasizing the importance of patient education in managing chronic respiratory conditions. As a result, the demand for resources and treatment options within The Global Emphysema Industry is likely to rise. ### Integration of Digital Health Solutions The integration of digital health solutions is reshaping The Global Emphysema Industry. Telehealth services and mobile health applications are becoming essential tools for managing chronic respiratory diseases, including emphysema. These technologies facilitate remote monitoring, enabling healthcare providers to track patient progress and adjust treatment plans accordingly. Market Research Future suggests that the telehealth market is expected to grow significantly, with projections indicating a value of over USD 250 billion by 2028. This trend not only enhances patient engagement but also improves access to care, particularly in underserved areas. Consequently, the adoption of digital health solutions is likely to drive growth within The Global Emphysema Industry. ### Advancements in Pharmaceutical Treatments Innovations in pharmaceutical treatments are transforming the landscape of The Global Emphysema Industry. Recent developments in bronchodilators and anti-inflammatory medications have shown promise in improving lung function and quality of life for patients. The introduction of novel therapies, such as biologics, is also gaining traction, potentially offering targeted treatment options for individuals with severe emphysema. Market data indicates that the global market for COPD medications is expected to reach approximately USD 20 billion by 2026, driven by these advancements. As healthcare providers increasingly adopt these innovative therapies, The Global Emphysema Industry is likely to experience substantial growth. ### Increased Investment in Research and Development The surge in investment in research and development (R&D) is a crucial driver for The Global Emphysema Industry. Pharmaceutical companies and research institutions are allocating substantial resources to explore new treatment modalities and improve existing therapies for emphysema. This focus on R&D is expected to yield innovative solutions that address unmet medical needs, thereby enhancing patient outcomes. Recent data indicates that global spending on R&D in the healthcare sector is projected to exceed USD 200 billion annually by 2025. As new therapies emerge from this investment, The Global Emphysema Industry is poised for significant advancements and growth. ## Future Outlook The Global Emphysema Market is projected to grow at a 4.83% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure. **New opportunities:** - Development of personalized inhalation therapies for targeted treatment. - - Expansion of telehealth services for remote patient monitoring. - Investment in AI-driven diagnostic tools for early detection. By 2035, the Emphysema Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access. ## Segment Insights ### By Type: Centrilobular (Largest) vs. Panlobular (Fastest-Growing) In The Global Emphysema Market, the segment of centrilobular emphysema holds a significant share, highlighting its prevalence among patients suffering from this respiratory condition. It is characterized by damage primarily affecting the central areas of the acini, leading to both airflow limitation and inflammation. This segment has been traditionally recognized for its impact on individuals, often associated with smoking and occupational dust exposure, contributing to its substantial market presence. On the other hand, panlobular emphysema is emerging as a rapidly growing segment due to increasing awareness of its unique impact on respiratory health, particularly among older adults and those with a genetic predisposition. This type of emphysema affects the entire acinus uniformly and is often associated with alpha-1 antitrypsin deficiency. Factors driving its growth include enhanced diagnostic capabilities and a rise in targeted therapies, drawing attention to its clinical significance. Centrilobular (Dominant) vs. Panlobular (Emerging) Centrilobular emphysema is characterized by the destruction of the respiratory bronchioles, a process often exacerbated by long-term cigarette smoking and environmental triggers. It typically manifests early in the disease continuum, establishing a strong market presence due to the large number of affected patients. In contrast, panlobular emphysema, while less prevalent, is gaining recognition as an emerging segment in the market. This type typically presents in a later stage of the disease and poses significant risks for patients, especially those with alpha-1 antitrypsin deficiency. The increasing emphasis on comprehensive disease management and patient education is propelling growth in this segment, leading to rising demand for innovative treatment options. ### By Diagnosis: Lung Function Test (Largest) vs. Imaging Test (Fastest-Growing) In The Global Emphysema Market, the 'Diagnosis' segment comprises various modalities including imaging tests and lung function tests. The lung function tests currently hold the largest market share, primarily due to their crucial role in evaluating airflow limitations and overall lung health. Imaging tests, while not holding the largest share, are gaining traction as they provide critical visual insights for diagnosis, thereby attracting increasing adoption among healthcare providers. Diagnosis Methods: Lung Function Test (Dominant) vs. Imaging Test (Emerging) Lung function tests are essential in diagnosing emphysema as they measure the lungs' ability to take in and utilize air. This method not only aids in confirming emphysema but also in assessing the severity and progression of the disease. Conversely, imaging tests, such as CT scans and X-rays, are emerging as vital diagnostic tools that offer detailed images of the lungs, thus enhancing the accuracy of diagnoses. As technology progresses, imaging tests are increasingly integrated with advanced analytics, suggesting a promising growth trajectory in the healthcare sector. ### By Treatment: Medications (Largest) vs. Therapy (Fastest-Growing) In The Global Emphysema Market, the Treatment segment is delineated primarily into medications, therapy, and surgery. Medications hold the largest share of the market, driven by their established efficacy in managing [symptoms](https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810) and improving quality of life for patients. On the other hand, therapy options, including pulmonary rehabilitation and other innovative treatments, are gaining traction, showcasing significant growth as healthcare providers focus on comprehensive patient care. The surgical interventions, while critical, represent a smaller portion of the market, typically reserved for advanced stages of the disease. Medications: Dominant vs. Therapy: Emerging Medications remain the dominant force in the Treatment segment, encompassing bronchodilators, corticosteroids, and combination therapies that significantly alleviate symptoms of emphysema. These pharmacological approaches are deeply embedded in treatment protocols and endorsed by healthcare professionals. Emerging therapies, on the other hand, focus on holistic patient management, emphasizing lifestyle changes and rehabilitation programs that enhance lung function and overall wellbeing. While medications are crucial for immediate disease management, therapy options are becoming increasingly recognized for their role in long-term patient health and quality of life, thus presenting a complementary route to traditional medication-based treatments. ### By End-User: Hospitals and Clinics (Largest) vs. Surgical Centers (Fastest-Growing) The Global Emphysema Market showcases a diverse distribution among its end-user segments, with hospitals and clinics holding a significant share owing to their comprehensive treatment capabilities for patients suffering from emphysema. This segment serves as a primary point of care, providing advanced therapies and interventions for this chronic lung condition. Whereas surgical centers are gaining traction, attributed to their specialization in procedures such as lung volume reduction surgery, leading to an uptick in their market presence. Hospitals and Clinics (Dominant) vs. Surgical Centers (Emerging) The 'Hospitals and Clinics' segment remains the dominant force in The Global Emphysema Market, primarily due to their well-established infrastructure, availability of specialized healthcare professionals, and comprehensive patient management systems. This segment is characterized by a holistic approach to treatment, incorporating both pharmaceuticals and therapeutic interventions. On the other hand, 'Surgical Centers' are emerging at a rapid pace, driven by increased patient awareness and demand for surgical options. These centers focus on minimally invasive techniques and personalized care, attracting patients seeking specialized treatments, thus reflecting a changing landscape in emphysema management. ## Regional Market Share Analysis ### North America : Healthcare Innovation Leader North America is the largest market for emphysema treatments, accounting for approximately 45% of the global market share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of respiratory diseases, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring timely access to innovative therapies. The United States and Canada are the leading countries in this region, with a competitive landscape dominated by major pharmaceutical companies such as GlaxoSmithKline, Pfizer, and AstraZeneca. These companies are actively involved in developing new therapies and improving existing treatments, contributing to a robust market environment. The presence of well-established healthcare systems and a high level of awareness among patients also bolster demand for effective emphysema management solutions. ### Europe : Regulatory Framework and Innovation Europe is the second-largest market for emphysema treatments, holding around 30% of the global market share. The region benefits from a strong regulatory framework that encourages innovation and ensures patient safety. Increasing awareness of chronic respiratory diseases and a growing aging population are key drivers of market growth. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new therapies, thus enhancing market dynamics. Leading countries in Europe include Germany, France, and the United Kingdom, where the presence of major pharmaceutical players like Boehringer Ingelheim and Novartis is significant. The competitive landscape is characterized by a mix of established companies and emerging biotech firms, all striving to develop novel treatment options. Collaborative efforts between public and private sectors further enhance research initiatives, ensuring a steady pipeline of innovative therapies for emphysema. ### Asia-Pacific : Emerging Market Potential Asia-Pacific is an emerging powerhouse in The Global Emphysema, accounting for approximately 20% of the market share. The region's growth is fueled by rising healthcare expenditures, increasing awareness of respiratory diseases, and a growing population. Countries like China and India are witnessing a surge in demand for effective treatment options, driven by urbanization and lifestyle changes that contribute to respiratory issues. China and Japan are the leading markets in this region, with a competitive landscape that includes both local and international players. Companies such as Teva Pharmaceutical Industries and Mylan are expanding their presence, focusing on affordable treatment options. The region's regulatory bodies are also becoming more supportive of innovative therapies, paving the way for new entrants and enhancing competition in the market. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa represent a growing market for emphysema treatments, holding about 5% of the global market share. The region is characterized by a rising prevalence of respiratory diseases, driven by factors such as pollution and smoking. Governments are increasingly recognizing the need for improved healthcare services, leading to regulatory initiatives aimed at enhancing access to treatment options for chronic respiratory conditions. Countries like South Africa and the United Arab Emirates are at the forefront of this market, with a competitive landscape that includes both multinational corporations and local manufacturers. Key players such as Sanofi and Roche are actively involved in expanding their product offerings in the region. The focus on public health initiatives and partnerships with healthcare providers is expected to drive market growth in the coming years. ## Competitive Benchmarking The Global Emphysema is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as GlaxoSmithKline (GB), Boehringer Ingelheim (DE), and AstraZeneca (GB) are actively engaged in enhancing their product portfolios and expanding their market reach. GlaxoSmithKline (GB) has positioned itself as a leader in respiratory therapies, emphasizing the development of novel inhalation devices and combination therapies. Meanwhile, Boehringer Ingelheim (DE) focuses on biologics and personalized medicine, aiming to tailor treatments to individual patient needs. AstraZeneca (GB) is leveraging its strong pipeline of biologics and small molecules to address unmet medical needs in emphysema, thereby enhancing its competitive edge. Collectively, these strategies indicate a market that is not only competitive but also increasingly collaborative, as companies seek to combine their strengths to deliver comprehensive solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and responsiveness to market demands. The Global Emphysema appears moderately fragmented, with several key players exerting significant influence. This structure allows for a diverse range of products and innovations, while also fostering competition that drives advancements in treatment options. The collective influence of these major players is pivotal in shaping market dynamics, as they navigate regulatory landscapes and adapt to evolving patient needs. In August 2025, Boehringer Ingelheim (DE) announced a strategic partnership with a leading digital health company to develop a comprehensive digital platform aimed at improving patient adherence to treatment regimens. This initiative is significant as it reflects a growing trend towards integrating technology with healthcare solutions, potentially enhancing patient outcomes and engagement. By leveraging digital tools, Boehringer Ingelheim (DE) is likely to strengthen its market position and foster loyalty among healthcare providers and patients alike. In September 2025, AstraZeneca (GB) launched a new inhalation therapy specifically designed for patients with severe emphysema. This product introduction is crucial as it addresses a significant gap in the current treatment landscape, offering a novel solution that could improve the quality of life for patients. The launch not only reinforces AstraZeneca's commitment to innovation but also positions the company to capture a larger share of the market by meeting the specific needs of this patient population. In October 2025, GlaxoSmithKline (GB) unveiled a new initiative focused on sustainability in its manufacturing processes, aiming to reduce carbon emissions by 30% over the next five years. This move is indicative of a broader trend within the industry towards sustainable practices, which are becoming increasingly important to stakeholders. By prioritizing sustainability, GlaxoSmithKline (GB) is likely to enhance its brand reputation and appeal to environmentally conscious consumers, thereby differentiating itself in a competitive market. As of October 2025, the competitive trends within The Global Emphysema are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient outcomes. Looking ahead, it is anticipated that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and the reliability of supply chains. This shift underscores the importance of adaptability and forward-thinking in maintaining a competitive edge in the dynamic landscape of The Global Emphysema. ## Report Scope | MARKET SIZE 2024 | 13.53(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 14.18(USD Billion) | | MARKET SIZE 2035 | 22.73(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.83% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | GlaxoSmithKline (GB), Boehringer Ingelheim (DE), AstraZeneca (GB), Novartis (CH), Roche (CH), Pfizer (US), Teva Pharmaceutical Industries (IL), Mylan (US), Sanofi (FR) | | Segments Covered | Type, Diagnosis, Treatment, End-User-Global Forecast till 2035 | | Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in The Global Emphysema. | | Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the emphysema treatment landscape. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of The Global Emphysema by 2035?** A: The projected market valuation of The Global Emphysema is 22.73 USD Billion by 2035. **Q: What was the market valuation of The Global Emphysema in 2024?** A: The market valuation of The Global Emphysema was 13.53 USD Billion in 2024. **Q: What is the expected CAGR for The Global Emphysema during the forecast period 2025 - 2035?** A: The expected CAGR for The Global Emphysema during the forecast period 2025 - 2035 is 4.83%. **Q: Which companies are considered key players in The Global Emphysema?** A: Key players in The Global Emphysema include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Roche, Pfizer, Teva Pharmaceutical Industries, Mylan, and Sanofi. **Q: What are the projected valuations for the centrilobular and panlobular segments by 2035?** A: The projected valuations for the centrilobular and panlobular segments are 11.36 USD Billion and 11.37 USD Billion, respectively, by 2035. **Q: How do the imaging test and lung function test segments compare in terms of projected valuation by 2035?** A: By 2035, the lung function test segment is projected to reach 11.0 USD Billion, while the imaging test segment is expected to reach 5.0 USD Billion. **Q: What is the expected valuation for the medications segment in The Global Emphysema by 2035?** A: The expected valuation for the medications segment in The Global Emphysema is 8.5 USD Billion by 2035. **Q: What are the projected valuations for hospitals and clinics as end-users by 2035?** A: The projected valuation for hospitals and clinics as end-users is 9.14 USD Billion by 2035. **Q: What is the expected growth trend for the therapy segment in The Global Emphysema?** A: The therapy segment is expected to grow to 6.5 USD Billion by 2035. **Q: How does the projected valuation for surgical centers compare to other end-user segments by 2035?** A: By 2035, the projected valuation for surgical centers is 6.06 USD Billion, which is lower than hospitals and clinics but higher than other end-user segments. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/emphysema-market-5810*